Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Sciences President Sells $17.2M in Shares Following Option Exercise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$26.6
Mkt Cap
$19.181B
52W Low
$8.73
52W High
$27.94
52W Position info
205% above low
Off High info
4.8% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $8.73.

Summary

Roivant Sciences' President and CIO, Mayukh Sukhatme, disposed of $17.2 million worth of common shares through a combination of open market sales and net settlement after exercising options, maintaining a flat share count but realizing significant cash.


Key Events · Ownership and Investor Activity · ROIV

  • President Disposes of $17.2M in Shares

    Mayukh Sukhatme, President and CIO, disposed of 651,558 shares totaling $17.2 million, comprising an $8.9 million open market sale and an $8.2 million net settlement to cover option exercise costs.

  • Cashless Option Exercise

    The disposition was part of a cashless exercise of 651,558 stock options, resulting in no net change to the insider's total share holdings.

  • Timing Near 52-Week Highs

    The transaction occurred on February 9, 2026, while the company's stock is trading near its 52-week high, following recent positive clinical trial results.


Analysis · ROIV · Life Sciences

This Form 4 filing indicates that Mayukh Sukhatme, President and CIO of Roivant Sciences, engaged in a cashless exercise of stock options. He acquired 651,558 shares and simultaneously disposed of an equivalent number of shares totaling $17.2 million. The disposition included an $8.9 million open market sale and an $8.2 million net settlement to cover the exercise price. This transaction follows recent positive Phase 2 results for brepocitinib and occurs while the stock is trading near its 52-week high. While the net share count for the insider remains unchanged, the substantial value of shares disposed for liquidity and to cover exercise costs represents a significant insider selling event, potentially signaling a move to lock in gains after recent positive developments. This continues a pattern of insider dispositions, as evidenced by recent Form 144 filings.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $26.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.2B. The 52-week trading range was $8.73 to $27.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $39.53 info
Change: -$1.84 (-4%) info
Market Cap: $28.642B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $39.53 info
Change: -$1.47 (-4%) info
Market Cap: $28.642B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $39.53 info
Change: -$0.860 (-2%) info
Market Cap: $28.642B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $39.53 info
Change: +$3.33 (+9%) info
Market Cap: $28.642B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $39.53 info
Change: +$2.93 (+8%) info
Market Cap: $28.642B info